Japanese drugmaker drops deal for a key MacroGenics drug

Rockville-based MacroGenics said it intends to continue efforts to advance one of its autoimmune disease drug candidates after it announced Monday that a Japanese drugmaker backed out of a licensing deal for the drug. Takeda Pharmaceutical Co. Ltd. said it would end a license and option agreement for MGD010, a MacroGenics (NASDAQ: MGNX) drug in a phase 1 clinical trial. Takeda officials said the decision was based on a "reprioritization on key therapeutic areas." On Monday, Takeda announced it…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news